Timing matters: neoadjuvant and adjuvant immunotherapy in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) carries a high-risk of recurrence following curative-intent therapies such as surgical resection or local ablation, largely due to residual micrometastatic disease and the immunosuppressive hepatic tumour microenvironment. Although immune checkpoint inhibitors (ICIs) have transformed the...